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Cervical cancer is one of the major causes of morbidity and mortality in women in Zimbabwe. This is mainly due
to the high prevalence of high-risk human papillomavirus (HPV) genotypes in the population. So far, few studies
have been done that showed the presence of high-risk genital HPV genotypes such as 16, 18, 31, 33, 52, 58 and 70
in Zimbabwean women with cervical cancer. The prevalence of HPV DNA in women with cervical cancer has been
shown to range from 63% to 98%. The high-risk HPV 16, 18, 31, 33 and 58 were the most common genotypes in all
the studies. The introduction of the new HPV vaccines, HPV2 and HPV4, which protect against HPV genotypes 16
and 18 into Zimbabwe is likely to go a long way in reducing deaths due to cervical cancer. However, there are few
challenges to the introduction of the vaccines. The target population for HPV vaccination is at the moment not
well-defined. The other challenge is that the current HPV vaccines confer only type-specific (HPV 16 and 18) immunity
leaving a small proportion of Zimbabwean women unprotected against other high-risk HPV genotypes such as
31, 33 and 58. Future HPV vaccines such as the nanovalent vaccine will be more useful to Zimbabwe as they will
protect women against more genotypes.Introduction
Human papillomaviruses (HPVs) are a group of highly
ubiquitous double-stranded circular DNA viruses that
infect cutaneous and mucosal surfaces [1]. They are di-
vided into low-risk and high-risk genotypes [2]. The
main low-risk genotypes are HPV genotypes 6, 11, 40,
42, 43, 44, 54, 61, 70, 72, 81 and the main high-risk
groups are HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68, 73, 82. It is now well established that
infection of the cervical tissue with the high-risk HPV
genotypes is a necessary cause of cervical cancer in
women [3-5]. At the moment, public knowledge of
HPV and cervical cancer is still lacking in Zimbabwe.
The lack of knowledge on cervical cancer and HPV
was also found during our previous cervical cancer
needs assessment study in 2 provinces of Zimbabwe a
few years ago [6].
The burden of cervical cancer in Zimbabwe
Zimbabwe is a low-income country in Southern Africa
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article, unless otherwise stated.Mozambique. According to the latest population census,
Zimbabwe has a population of 12,5 million people of
which approximately half are female. Nationally, the
Ministry of Health and Child Care has the primary
responsibility of providing health care services to the
majority of the population, including maternal and re-
productive health services such as prevention and
treatment of cervical cancer. Worldwide, cervical can-
cer is the second most common malignancy in women
[7]. Almost 80% of cervical cancer cases are found in
low income level countries [8,9]. In most African coun-
tries, cervical cancer is a leading cause of death in
women [10]. The age-standardised incidence rates of
cervical cancer in Africa ranges from 42.7 to 12.1 per
100 000 women [11]. In Zimbabwe, cervical cancer is
an important reproductive health problem and is a
major cause of mortality and morbidity in women than
any other cancers [12]. It accounts for 32.2% of all
female cancers and is the most common [12]. The age-
adjusted incidence rate of cervical cancer in Zimbabwe
is estimated at about 52.1 per 100,000 women and age-
adjusted mortality rate is 43.1% [13]. The exact number of
women suffering and dying from cervical cancer is likely
to be higher than those quoted by the Zimbabwe National
Cancer Registry as there are many women dying of thetral Ltd. This is an Open Access article distributed under the terms of the
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the women who die have never attended a health facility
up to the time of their death.
HPV genotypes in cervical cancer in Zimbabwe
In Zimbabwe, a number of studies have been done to
evaluate high-risk HPV genotypes present in women
with cervical cancer. Firstly, a cross-sectional study (n =
119) was done to investigate the prevalence of low-risk
and high-risk HPV genotypes in women with cervical
cancer at two referral hospitals, Harare Central and
Parirenyatwa Hospitals in Harare in Zimbabwe [14].
Using the Hybrid Capture assay, HPV DNA was de-
tected in 63% of the cervical swabs. The prevalence of
any of the high-risk HPV genotypes (16, 18, 31, 33, 35,
45, 51, 52 and 56) was 51%. The low-risk HPV genotypes
(6, 11, 42, 43 and 44) were detected in 26% of the samples.
In this study, dual infection with both the low-risk and
high-risk HPV genotypes was found in 14% of the cases.
This was the first study to show an association of certain
HPV genotypes with cervical cancer in Zimbabwe. In a sec-
ond study in Harare, the presence of HPV genotypes in cer-
vical swabs and urine collected from Zimbabwean women
(n = 43) who had cervical cancer was conducted using re-
striction fragment length polymorphism-polymerase chain
reaction [RFLP-PCR] [15]. Of all the women studied, 98%
and 72% had HPV DNA in cervical swabs and urine sam-
ples respectively. In this study, the high-risk HPV 16 was
the most prevalent genotype and was found in 59% of the
cervical samples. HPV 33 was found in 31% of the samples
followed by HPV 18 (14%), HPV 31 (2%) and HPV 58 (2%).
It was also noted in this study that the HPV genotypes
found in the urine samples were the same as those found in
the cervical samples. Of the 28 urines samples typed, 61%,
16%, 13% and 3% had HPV 16, 33, 18 and 31 genotypes re-
spectively. According to this study, HPV 33 was the second
commonest genotypes found in Zimbabwe and is not cov-
ered by the current two HPV vaccines on the market.
In a third study with 98 Zimbabwean women with cer-
vical cancer in Harare, HPV genotypes were also investi-
gated [16]. The HPV DNA was detected in 97% of the
samples. Of the cases, HPV 16, 33, 18 and 31 genotypes
were found in 61%, 39%, 18% and 4% of the samples re-
spectively. HPV 35 and 58 were also found in some sam-
ples. It was also noted in this study that some patients
who were dually infected with both HPV 16 and HPV
33 and most of them were young (10–13 age-group).
Another study was conducted to determine cervical HPV
incidence in a cohort of 2040 HIV-negative Zimbabwean
women [17]. The prevalence of HPV genotypes, 58, 16, 70,
18, 33, 53, 52 and 31 was 5.0%, 4.7%, 2.4%, 2.3%, 2.0%,
1.8%, 1.3% and 1.3% respectively [17]. This study showed
that the high-risk HPV 58 was more common than geno-
type 16 or 18 that are covered by the current HPV vaccines.Overall, these few studies mentioned above highlight the
need to have HPV vaccines in Zimbabwe that will cover all
most prevalent genotypes.
Risk factors of cervical cancer in Zimbabwe
It is now generally agreed that persistent infection by
high-risk HPV genotypes is the major cause of cervical
cancer [18]. There are several risk factors that universally
predispose women to acquiring high-risk HPVs that may
cause cervical cancer [19]. The factors include multiparity,
early age of first intercourse, multiple sexual partners, poor
genital hygiene, use of oral steroid contraceptives, cigarette
smoking, some dietary factors and infection with other
sexually transmitted pathogens such as Chlamydia tracho-
matis and herpes simplex virus which cause chronic cervi-
covaginal inflammation [20-23]. In addition to the above
factors, there are other cofactors such as host genetic fac-
tors and immunodeficiency that are considered to be also
important for development and progression of cervical can-
cer [20,24]. Other factors such as race and ethnicity are also
important risk factors of cervical cancer [25]. African
women are at a higher risk of developing cervical cancer
than their Caucasian counterparts [22,26]. Our research
group at the University of Zimbabwe also previously carried
out a national cervical cancer needs assessment study of
Zimbabwean (African) women in two provinces [6]. Some
of the risk factors of cervical cancer were investigated. From
the study, it was noted that 76% of cervical cancer in
Zimbabwe presented late at health care facilities. The high
percentage of women (44%) in the study did not use con-
traceptives such as condoms that can protect against HPV
acquisition. Only 4% of married couples used barrier/con-
doms. The mean parity was 5 children. Sexual activity in
Zimbabwean girls was found to start at 15 and this was
likely to predispose them to HPV infection at an early age.
From the study, it was also noted that knowledge of cervical
cancer and HPVs was very low in the population. The study
highlighted some of the risk factors that predisposed
women to HPV infection and the gaps in prevention of cer-
vical cancer in Zimbabwe.
HPV vaccination and challenges in Zimbabwe
Two HPV vaccines have recently been developed to pre-
vent cervical cancer in women [27,28]. In Zimbabwe,
considerations are now being made to vaccinate girls
and women against HPV using the two recently licensed
subunit vaccines, HPV2 and HPV4. The vaccines are
now available in the private sector and will be intro-
duced into the public health institutions soon. HPV2 is a
bivalent vaccine that prevents mainly HPV-16 and HPV-
18, while HPV4 is a quadrivalent vaccine that prevents
infection by HPV-16, HPV-18, HPV 6 and HPV 11 ge-
notypes. The two vaccines have been shown to be effect-
ive and efficacious in preventing cervical cancer caused
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by HPV 6 and 11 genotypes [29-32]. Although the two
vaccines can be very helpful in reducing cervical cancer
mortality in the long-term, their introduction in Zimbabwe
is likely to meet several challenges. Since the two vaccines
only target HPV genotypes 6, 11, 16, and 18, the vaccines
may not be effective in protecting against other HPV geno-
types that are common in Zimbabwe and cause cervical
cancer. According to studies mentioned above, the high-
risk HPV genotypes 31, 33 and 58 were also found in a sub-
stantial proportion of women with cervical cancer [14-16].
Women infected with such genotypes will not be fully pro-
tected from getting cervical cancer by the current vaccines.
This challenge has also been observed in other African
countries such as Zambia, Cameroun, Mozambique and
Senegal where other non-16 and 18 genotypes were preva-
lent [33-36]. Although cross-protection against multiple
genotypes by the current HPV vaccines may occur, it is not
absolute [37-39]. The challenge therefore confirms the
importance of developing HPV vaccines for genotypes
common in African women. The new HPV nanovalent vac-
cine still in clinical trials [40] will be more useful in
Zimbabwe and other Sub-Saharan African countries since
it may protect against more HPV genotypes (6/11/16/18/
31/33/45/52/58).
There are other HPV vaccination challenges in
Zimbabwe. The target group for HPV vaccination has
not yet been defined. Generally, girls should be tar-
geted for HPV vaccination before the onset of sexual
activities [41]. No studies on HPV infection in girls or
boys of this age-group have been done in Zimbabwe.
Epidemiological studies are still required to ascertain the
HPV prevalence by age and sex in Zimbabwe. The other
challenge to HPV vaccination in Zimbabwe is the prohibi-
tive cost ($180 - $300 for 3 doses in the private health care
sector) of the vaccines to most people. Although the cost
is high, the vaccines are readily available in the private
sector. In the public health care sector, government or
donor funding may have to subsidize the vaccines if more
girls and women are to be reached. The funding for an
HPV Vaccine Demonstration Project has been sourced
from donors such as Global Alliance for Vaccine and
Immunization (GAVI), UNICEF, WHO and UNFPA. The
HPV vaccines will be introduced to two districts of
Marondera and Beitbridge and will be targeted to adoles-
cent girls aged 10 years. The government of Zimbabwe
will assist with funding for the implementation of the
project. It is hoped that the demonstration project will
provide data that can be used for future national HPV
vaccine rollout.
In Zimbabwe, as in most developing countries, there
are no national cervical cancer screening or HPV testing
programmes. Although 80% of all cervical cancers occur
in developing countries, only about 5% of the at-riskwomen are screened for cervical cancer [42]. Screening
of cervical cancer using cytology, visual inspection as
well as HPV testing can reduce the high mortality in
women in Zimbabwe. It has been suggested that HPV
testing and cytology together would increase the chance of
detecting cervical cancer by about 35% [43]. No services for
HPV testing in public and private sector are available.
Cervical cancer prevention and control through screening
and HPV vaccination should therefore be a national priority
if women are to be saved from dying from cervical cancer, a
preventable disease.
Conclusion
Cervical cancer caused by high-risk HPV genotypes
accounts for substantial morbidity and mortality in
Zimbabwe. The government is now planning to intro-
duce HPV vaccines in girls in 2014 and the potential
usefulness of these vaccines cannot be underestimated.
Although there are few challenges, the HPV vaccines
are likely to go a long way in reducing the prevalence
of cervical cancer in Zimbabwean women.
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